NNMT Upregulation: The Hidden Methylation Cost of Nicotinamide Supplementation

The hype surrounding NAD+ precursors often glosses over the metabolic disposal of these compounds. When you supplement with high doses of Nicotinamide (NAM), the body must process the excess to prevent the inhibition of sirtuins and PARP enzymes (as NAM is a feedback inhibitor of these processes). This is primarily handled by the enzyme Nicotinamide N-methyltransferase (NNMT), which attaches a methyl group from S-adenosylmethionine (SAMe) to the nicotinamide, creating methylnicotinamide (MNA) for excretion. The biological danger lies in the 'Methyl Drain.' SAMe is the universal methyl donor required for DNA methylation, the synthesis of creatine, and the breakdown of histamine and neurotransmitters like dopamine. By flooding the system with NAM, you force the body to prioritize the neutralization of B3 over crucial epigenetic maintenance.

In the UK, where MTHFR polymorphisms are common, this can lead to a rapid depletion of methyl pools, elevated homocysteine, and increased risk of cardiovascular and neurological issues. Research indicates that NNMT is often upregulated in obesity and metabolic syndrome, where it further contributes to metabolic rigidity by depleting methyl groups available for regulating energy metabolism. This suggests that the 'more is better' approach to NAD+ supplementation is fundamentally flawed. To protect the methyl pool, individuals should prioritize precursors that bypass the immediate generation of NAM, such as NMN or NR, and always pair them with methyl donors like TMG (Trimethylglycine) or methylcobalamin. Furthermore, supporting the 'salvage pathway'—which recycles NAM back into NAD+ via the enzyme NAMPT—is a cleaner strategy than simply dumping more raw material into a broken system.

Understanding NNMT biology allows for a more nuanced approach to supplementation that respects the interconnectedness of methylation and redox chemistry.